Kate Wiles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kate Wiles has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Charlotte Frise
COxford University Hospitals NHS Foundation Trust, Oxford, UK and Queen Charlotte’s and Chelsea Hospital, London, UK
1 shared publicationF. Conti-Ramsden
Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, London, England
1 shared publicationL.C. Chappell
Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, London, England
1 shared publication- Liz Lightstone
Imperial College London Faculty of Medicine, London, United Kingdom
1 shared publication M. Rutherford
Kings Coll London, Ctr Developing Brain, London, England
1 shared publicationMellisa Damodaram
BQueen Charlotte’s and Chelsea Hospital, London, UK
1 shared publication
Latest Publications
- 9 October 2023
- Published by SAGE Publications in Obstetric Medicine
- Vol. 17 (2) , 96-100
Pregnancy in women with nephrotic-range proteinuria: A retrospective cohort study
Background: Obstetric and kidney outcomes following detection of nephrotic-range proteinuria in early pregnancy have not been well described. Methods: A retrospective cohort study of chronic kidney disease (CKD) in pregnancy between 2008 and 2018. Outcomes in those with nephrotic-range proteinuria before 20 weeks’ gestation were compared to those without nephrotic-range proteinuria. Results: The study included 37 women with nephrotic-range proteinuria and 62 women without. Pre-pregnancy estimated glomerular filtration rate (eGFR) was similar. Nephrotic-range proteinuria was associated with higher rates of preterm (odds ratio [OR] 1.77, 95% confidence interval [CI]: 1.07–2.92) and early preterm delivery (OR 2.63, 95% CI: 1.12–6.2), and with a requirement for renal replacement therapy at 3 years post-partum (OR 10.72, 95% CI: 2.58–44.47). Tubulointerstitial scarring on kidney biopsy was associated with early preterm delivery and progression to advanced CKD, independent of pre-pregnancy eGFR. Conclusion: Compared to CKD without nephrotic-range proteinuria, nephrotic-range proteinuria early in pregnancy is associated with higher rates of pre-term delivery and progression to advanced CKD.
- 9 October 2023
- Published by SAGE Publications in Obstetric Medicine
- Vol. 17 (2) , 96-100
Pregnancy in women with nephrotic-range proteinuria: A retrospective cohort study
Background: Obstetric and kidney outcomes following detection of nephrotic-range proteinuria in early pregnancy have not been well described. Methods: A retrospective cohort study of chronic kidney disease (CKD) in pregnancy between 2008 and 2018. Outcomes in those with nephrotic-range proteinuria before 20 weeks’ gestation were compared to those without nephrotic-range proteinuria. Results: The study included 37 women with nephrotic-range proteinuria and 62 women without. Pre-pregnancy estimated glomerular filtration rate (eGFR) was similar. Nephrotic-range proteinuria was associated with higher rates of preterm (odds ratio [OR] 1.77, 95% confidence interval [CI]: 1.07–2.92) and early preterm delivery (OR 2.63, 95% CI: 1.12–6.2), and with a requirement for renal replacement therapy at 3 years post-partum (OR 10.72, 95% CI: 2.58–44.47). Tubulointerstitial scarring on kidney biopsy was associated with early preterm delivery and progression to advanced CKD, independent of pre-pregnancy eGFR. Conclusion: Compared to CKD without nephrotic-range proteinuria, nephrotic-range proteinuria early in pregnancy is associated with higher rates of pre-term delivery and progression to advanced CKD.
- Open Access
- 13 May 2022
- Published by Elsevier in Clinical Radiology
- Vol. 77 (7) , 548-552
Kidney morphology in pregnancy using T2-weighted MRI
- 13 May 2022
- Published by Elsevier in Clinical Radiology
- Vol. 77 (7) , 548-552
Open AccessKidney morphology in pregnancy using T2-weighted MRI
- Open Access
- 1 September 2021
- Published by Elsevier in Clinical Medicine
- Vol. 21 (5) , e451-e456
Severe hypertension in pregnancy
Severe hypertension in pregnancy is defined as a sustained systolic blood pressure of 160 mmHg or over or diastolic blood pressure of 110 mmHg or over and should be assessed in hospital. Severe hypertension before 20 weeks’ gestation is rare and usually due to chronic hypertension; assessment for target organ damage and exclusion of secondary hypertension are warranted. The most common cause of severe hypertension in pregnancy is pre-eclampsia, which presents after 20 weeks’ gestation. This warrants more rapid control of blood pressure due to the risk of haemorrhagic stroke, and intravenous antihypertensive agents may be required. Treatment is determined by licensing, availability and clinician experience, with no high-level evidence to guide prescribing. Labetalol is the agent most commonly used, both orally and intravenously, in pregnancy in the UK. Severe hypertension is a risk factor for sustained hypertension after pregnancy. Hypertension in pregnancy is associated with increased cardiovascular risk.
- 1 September 2021
- Published by Elsevier in Clinical Medicine
- Vol. 21 (5) , e451-e456
Open AccessSevere hypertension in pregnancy
Severe hypertension in pregnancy is defined as a sustained systolic blood pressure of 160 mmHg or over or diastolic blood pressure of 110 mmHg or over and should be assessed in hospital. Severe hypertension before 20 weeks’ gestation is rare and usually due to chronic hypertension; assessment for target organ damage and exclusion of secondary hypertension are warranted. The most common cause of severe hypertension in pregnancy is pre-eclampsia, which presents after 20 weeks’ gestation. This warrants more rapid control of blood pressure due to the risk of haemorrhagic stroke, and intravenous antihypertensive agents may be required. Treatment is determined by licensing, availability and clinician experience, with no high-level evidence to guide prescribing. Labetalol is the agent most commonly used, both orally and intravenously, in pregnancy in the UK. Severe hypertension is a risk factor for sustained hypertension after pregnancy. Hypertension in pregnancy is associated with increased cardiovascular risk.